The Hippo signaling pathway is a master regulator of development, cell proliferation, and apoptosis in particular, and it plays an important role in tissue regeneration, controlling organ size, and cancer suppression. Dysregulation of the Hippo signaling pathway has been implicated in breast cancer, a highly prevalent cancer affecting 1 out of every 15 women worldwide. While the Hippo signaling pathway inhibitors are available, they are suboptimal, for example, due to chemoresistance, mutation, and signal leakage. Inadequate knowledge about the Hippo pathway connections and their regulators limits our ability to uncover novel molecular targets for drug development. We report here novel microRNA (miRNA)-gene and protein–protein interaction networks in the Hippo signaling pathway. We employed the GSE miRNA dataset for the present study. The GSE57897 dataset was normalized and searched for differentially expressed miRNAs, and their targets were searched using the miRWalk2.0 tool. From the upregulated miRNAs, we observed that the hsa-miR-205-5p forms the biggest cluster and targets four genes involved in the Hippo signaling pathway. Interestingly, we found a novel connection between two Hippo signaling pathway proteins, angiomotin (AMOT) and mothers against decapentaplegic homolog 4 (SMAD4). From the downregulated miRNAs, hsa-miR-16-5p, hsa-miR-7g-5p, hsa-miR-141-3p, hsa-miR-103a-3p, hsa-miR-21-5p, and hsa-miR-200c-3p, target genes were present in the pathway. We found that PTEN, EP300, and BTRC were important cancer-inhibiting proteins, form hubs, and their genes interact with downregulating miRNAs. We suggest that targeting proteins from these newly unraveled networks in the Hippo signaling pathway and further research on the interaction of hub-forming cancer-inhibiting proteins can open up new avenues for next-generation breast cancer therapeutics.
Get full access to this article
View all access options for this article.
References
1.
AsaduzzamanM, ConstantinouS, MinH, et al.Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. Breast Cancer Res Treat, 2017; 163(3):461–474; doi: 10.1007/s10549-017-4202-z
2.
AstamalRV, MaghoulA, TaefehshokrS, et al.Regulatory role of microRNAs in cancer through Hippo signaling pathway. Pathol Res Pract, 2020; 216(12):153241; doi: 10.1016/j.prp.2020.153241
3.
BendinelliP, MaroniP, MatteucciE, et al.Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer. Eur J Cancer, 2013; 49(11):2608–2618; doi: 10.1016/j.ejca.2013.03.002
4.
CamargoFD, GokhaleS, JohnnidisJB, et al.YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol, 2007; 17(23):2054–2060; doi: 10.1016/j.cub.2007.10.039
5.
ChenCY, ChenJ, HeL, et al.PTEN: Tumor suppressor and metabolic regulator. Front Endocrinol (Lausanne), 2018; 9:338; doi: 10.3389/fendo.2018.00338
6.
ChenK, RajewskyN. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet, 2007; 8(2):93–103; doi: 10.1038/nrg1990
7.
Diaz-MartinJ, Lopez-GarciaMA, Romero-PerezL, et al.Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocr Relat Cancer, 2015; 22(3):443–454; doi: 10.1530/ERC-14-0456
8.
DongJ, FeldmannG, HuangJ, et al.Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell, 2007; 130(6):1120–1133; doi: 10.1016/j.cell.2007.07.019
9.
EnrightAJ, Van DongenS, OuzounisCA. An efficient algorithm for large-scale detection of protein families. Nucleic Acids Res, 2002; 30(7):1575–1584; doi: 10.1093/nar/30.7.1575
10.
GoedhartJ, LuijsterburgMS. VolcaNoseR is a web app for creating, exploring, labeling and sharing volcano plots. Sci Rep, 2020; 10(1):20560; doi: 10.1038/s41598-020-76603-3
11.
GuoD, GuoJ, LiX, et al.Enhanced motility and proliferation by miR-10b/FUT8/p-AKT axis in breast cancer cells. Oncol Lett, 2018; 16:2097–2104.
12.
HaghiM, TahaMF, JaveriA. Suppressive effect of exogenous miR-16 and miR-34a on tumorigenesis of breast cancer cells. J Cell Biochem, 2019; 120:13342–13353.
13.
HuangJ, WuS, BarreraJ, et al.The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell, 2005; 122(3):421–434; doi: 10.1016/j.cell.2005.06.007
14.
HuangT, ZhouY, ZhangJ, et al.The physiological role of Motin family and its dysregulation in tumorigenesis. J Transl Med, 2018; 16(1):98; doi: 10.1186/s12967-018-1466-y
15.
ImaiY, KurokawaM, IzutsuK, et al.Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. Oncogene, 2001; 20(1):88–96; doi: 10.1038/sj.onc.1204057
16.
JiaoX, ShermanBT, Huang daW, et al.DAVID-WS: A stateful web service to facilitate gene/protein list analysis. Bioinformatics, 2012; 28(13):1805–1806; doi: 10.1093/bioinformatics/bts251
17.
KabekkoduSP, ShuklaV, VargheseVK, et al.Cluster miRNAs and cancer: Diagnostic, prognostic and therapeutic opportunities. Wiley Interdiscip Rev RNA, 2020; 11(2):e1563; doi: 10.1002/wrna.1563
18.
KandettuA, RadhakrishnanR, ChakrabartyS, et al.The emerging role of miRNA clusters in breast cancer progression. Biochim Biophys Acta Rev Cancer, 2020; 1874(2):188413; doi: 10.1016/j.bbcan.2020.188413
19.
KanehisaM, GotoS. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res, 2000; 28(1):27–30; doi: 10.1093/nar/28.1.27
20.
KongW, HeL, RichardsE, et al.Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene, 2013; 33:679–689.
21.
KrolJ, LoedigeI, FilipowiczW. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet, 2010; 11(9):597–610; doi: 10.1038/nrg2843
22.
LeeJH, KimTS, YangTH, et al.A crucial role of WW45 in developing epithelial tissues in the mouse. EMBO J, 2008; 27(8):1231–1242; doi: 10.1038/emboj.2008.63
23.
LiuF, PouponnotC, MassagueJ. Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev, 1997; 11(23):3157–3167; doi: 10.1101/gad.11.23.3157
24.
Maugeri-SaccaM, BarbaM, PizzutiL, et al.The Hippo transducers TAZ and YAP in breast cancer: Oncogenic activities and clinical implications. Expert Rev Mol Med, 2015; 17:e14; doi: 10.1017/erm.2015.12
25.
MittalP, SinghS, SinhaR, et al.Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy. Int J Biol Macromol, 2021; 187:999–1018; doi: 10.1016/j.ijbiomac.2021.07.166
26.
MohajanS, JaiswalPK, VatanmakarianM, et al.Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer. Cancer Lett, 2021; 507:112–123; doi: 10.1016/j.canlet.2021.03.006
27.
MorrisJH, ApeltsinL, NewmanAM, et al.clusterMaker: A multi-algorithm clustering plugin for Cytoscape. BMC Bioinform, 2011; 12:436; doi: 10.1186/1471-2105-12-436
28.
RuiX, ZhaoH, XiaoX, et al.MicroRNA-34a suppresses breast cancer cell proliferation and invasion by targeting Notch1. Exp Ther Med, 2018; 16:4387–4392.
29.
SandM, SkryganM, GeorgasD, et al.Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer. Mol Carcinog, 2012; 51(11):916–922; doi: 10.1002/mc.20861
30.
SeongHA, JungH, KimKT, et al.3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth factor-beta-induced signaling in a kinase-dependent manner through physical interaction with Smad proteins. J Biol Chem, 2007; 282(16):12272–12289; doi: 10.1074/jbc.M609279200
31.
ShannonP, MarkielA, OzierO, et al.Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 2003; 13(11):2498–2504; doi: 10.1101/gr.1239303
32.
SongY, MaX, ZhangM, et al.Ezrin mediates invasion and metastasis in tumorigenesis: A review. Front Cell Dev Biol, 2020; 8:588801; doi: 10.3389/fcell.2020.588801
33.
StichtC, De La TorreC, ParveenA, et al.miRWalk: An online resource for prediction of microRNA binding sites. PLoS One, 2018; 13(10):e0206239; doi: 10.1371/journal.pone.0206239
34.
StinsonS, LacknerMR, AdaiAT, et al.miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci Signal, 2011; 4:pt5–pt5.
35.
SzklarczykD, GableAL, LyonD, et al.STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res, 2019; 47(D1):D607–D613; doi: 10.1093/nar/gky1131
36.
TakedaT, YamamotoH, KanzakiH, et al.Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. PLoS One, 2017; 12(2):e0171356; doi: 10.1371/journal.pone.0171356
37.
TomczakA, MortensenJM, WinnenburgR, et al.Interpretation of biological experiments changes with evolution of the Gene Ontology and its annotations. Sci Rep, 2018; 8(1):5115; doi: 10.1038/s41598-018-23395-2
38.
TroyanovskyB, LevchenkoT, ManssonG, et al.Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol, 2001; 152(6):1247–1254; doi: 10.1083/jcb.152.6.1247
39.
van DongenS, Abreu-GoodgerC. Using MCL to extract clusters from networks. Methods Mol Biol, 2012; 804:281–295; doi: 10.1007/978-1-61779-361-5_15
40.
VermaP, MittalP, SinghA, et al.New entrants into clinical trials for targeted therapy of breast cancer: An insight. Anticancer Agents Med Chem, 2019; 19(18):2156–2176; doi: 10.2174/1871520619666191018172926
XiangL, GilkesDM, HuH, et al.HIF-1alpha and TAZ serve as reciprocal co-activators in human breast cancer cells. Oncotarget, 2015; 6(14):11768–11778; doi: 10.18632/oncotarget.4190
43.
XiaoX, HuangX, YeF, et al.The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer. Sci Rep, 2016; 6:21735.
44.
YanL, HuangX-F, ShaoQ, et al.MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 2008; 1411:2348–2360.
45.
YangY, CuiJ, XueF, et al.Pokemon (FBI-1) interacts with Smad4 to repress TGF-beta-induced transcriptional responses. Biochim Biophys Acta, 2015; 1849(3):270–281; doi: 10.1016/j.bbagrm.2014.12.008
46.
YangZ, HataY. What is the Hippo pathway? Is the Hippo pathway conserved in Caenorhabditis elegans?. J Biochem, 2013; 154(3):207–209; doi: 10.1093/jb/mvt060
47.
YoshidaK, YokoiA, YamamotoY, et al.ChrXq27.3 miRNA cluster functions in cancer development. J Exp Clin Cancer Res, 2021; 40(1):112; doi: 10.1186/s13046-021-01910-0
48.
ZanconatoF, CordenonsiM, PiccoloS. YAP/TAZ at the roots of cancer. Cancer Cell, 2016; 29(6):783–803; doi: 10.1016/j.ccell.2016.05.005
49.
ZhangR, ZhangS, XingR, et al.High expression of EZR (ezrin) gene is correlated with the poor overall survival of breast cancer patients. Thorac Cancer, 2019; 10(10):1953–1961; doi: 10.1111/1759-7714.13174
50.
ZhaoG, GuoJ, LiD, et al.MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7cell line. DNA Cell Biol, 2013; 32(12):699–707.
51.
ZhaoXG, HuJY, TangJ, et al.miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell Death Dis, 2019; 10(7):479; doi: 10.1038/s41419-019-1705-z
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
